4.7 Article

Comparative 28-day repeated oral toxicity of Longdan Xieganwan, Akebia trifoliate (Thunb.) koidz., Akebia quinata (Thunb.) Decne. and Caulis aristolochiae manshuriensis in mice

Journal

JOURNAL OF ETHNOPHARMACOLOGY
Volume 119, Issue 1, Pages 87-93

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.jep.2008.05.037

Keywords

oral toxicity; Longdan Xieganwan; Akebia trifoliate (Thunb.) koidz.; Akebia quinata (Thunb.) Decne.; Caulis aristolochiae manshuriensis; no-observed-adverse-effect level

Funding

  1. National Grand Fundamental Research 973 Program of China [2006CB504700]

Ask authors/readers for more resources

Ethnopharmacological relevance: Longdan Xieganwan, which contains Aristolochia species, is a traditional Chinese prescription. It has been used for thousands of years to enhance liver. However, many cases of Longdan Xieganwan induced nephropathy were reported recently. Aim of the study: This study was designed to compare the possible toxic effects of Longdan Xieganwan and three different Aristolochia species. i.e. Akebia trifoliate (Thunb.) koid (Akebia trifoliate), Akebia quinata (Thunb.) Decne. (Akebia quinata) and Caulis aristolochiae manshuriensis (Aristolochia manshuriensis). Materials and methods: Mice were orally administered these drugs for 28 days. Clinical signs, body weights, serum biochemistry, organ weights and histopathology were examined. Results: Significantly decreased body weights and obvious nephropathy were noticed in the Aristolochia manshuriensis groups at doses higher than 0.24g/kg/d. A few endothelial cell degenerations in renal glomerulus were observed in the Akebia trifoliate group at a high-dose of 2.00 g/kg/d. No significant changes were observed in the other groups. Conclusions: The no-observed-adverse-effect levels (NOAELs) for Aristolochia manshuriensis, Akebia trifoliate, Akebia quinata and Longdan Xieganwan in this study for mice were 0.06 g/kg/d, 0.40 g/kg/d, higher than 3.00 g/kg/d and higher than 10.00 g/kg/d, which were equivalent to 0.25 times, 5 times, 25 times and 10 times of normal human dose in clinical prescription, respectively. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available